Goldman Sachs
BCRX icon

Goldman Sachs’s BioCryst Pharmaceuticals BCRX Stock Holding History

Goldman Sachs’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-190,600
Closed -$999K – 6343
2017
Q3 		$999K Buy
190,600
+12,600
+7% +$64.5K ﹤0.01% 4569
2017
Q2 		$990K Buy
+178,000
New +$1.08M ﹤0.01% 4466

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Goldman Sachs's BCRX Position: Q2 2026 in Review

Goldman Sachs increased its BioCryst Pharmaceuticals (BCRX) stake by 91% in Q2 2026, buying an estimated $19.3M and bringing the position to 4,481,874 shares worth $44.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Goldman Sachs first reported a position in BCRX in Q2 2013 and has held it in 53 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Goldman Sachs held 4,481,874 shares of BioCryst Pharmaceuticals worth $44.8M as of Q2 2026.
  • Goldman Sachs bought 2,134,431 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $19.3M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1906 holding.
  • Goldman Sachs first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.